Personalized drug approach aims to make cancer transplants safer
NCT ID NCT04872595
Summary
This study is testing if adjusting the dose of a drug called rabbit ATG based on a patient's individual needs can help the immune system recover faster after a stem cell transplant. The goal is to reduce serious side effects and improve survival for children and adults with certain blood cancers like leukemia. Participants will receive a standard transplant preparation regimen that includes this personalized drug dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.